Alva-based life sciences firm Omega hails approval for Covid test in India
The medical diagnostics company said its CE-Marked Mologic Elisa (Enzyme Linked Immuno-Sorbent Assay) antibody test has been given the thumbs-up by the Asian country’s authorities.
Omega said approval for sale remains conditional on submitting supporting technical data, and the firm expects this to be successful, enabling it to sell its Elisa antibody test directly into the “potentially significant” target market.
The test has high-quality performance data and has been independently validated by the Liverpool School of Tropical Medicine and St George’s, University of London, added Omega, whose remit also encompasses testing related to HIV, infectious diseases and food intolerance,
The Scottish firm said that while the quantum of future sales is unknown at this stage, India is “clearly a significant addressable market for Covid-19 antibody testing and Omega will use its direct sales team in India to establish commercial roll-out in the region”.
Omega chief executive Colin King welcomed approval to sell the test in India as it is a key target market. He added: “We have an established direct sales team and we believe a reliable and high-performance antibody test will be very attractive to our laboratory customers.
“India is one of the fastest-growing economies in the world and has a population of over 1.3 billion. Clearly, this is an important market for us to target and I look forward to updating shareholders on our commercial traction.”
A message from the Editor:
Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.
The dramatic events of 2020 are having a major impact on many of our advertisers - and consequently the revenue we receive. We are now more reliant than ever on you taking out a digital subscription to support our journalism.
By supporting us, we are able to support you in providing trusted, fact-checked content for this website.
Want to join the conversation? Please or to comment on this article.